CCM
DMRA

CAAS Capital Management’s Damora Therapeutics DMRA Stock Holding History

CAAS Capital Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-800
Closed -$250K – 1257
2020
Q4 		$250K Buy
+800
New +$298K ﹤0.01% 747

Other funds holding DMRA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

CAAS Capital Management's DMRA Position: Q1 2021 in Review

CAAS Capital Management sold out of Damora Therapeutics (DMRA) in Q1 2021, closing a stake of 800 shares — an estimated $250K sold.

CAAS Capital Management first reported a position in DMRA in Q4 2020 and held it in 1 quarter. The position peaked at $250K in Q4 2020. 19 funds tracked by Wall St. Rank hold DMRA as of Q1 2021.

  • CAAS Capital Management reported no remaining Damora Therapeutics position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 800 Damora Therapeutics shares in Q1 2021, an estimated $250K.
  • CAAS Capital Management first reported a position in Damora Therapeutics in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's Damora Therapeutics position peaked at $250K in Q4 2020.
  • 19 funds tracked by Wall St. Rank held Damora Therapeutics as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.